- Home
- LCTX vs ALEC Comparison
LCTX vs ALEC Comparison
Compare LCTX & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- ALEC
- Stock Information
- Founded
- LCTX 1990
- ALEC 2013
- Country
- LCTX United States
- ALEC United States
- Employees
- LCTX N/A
- ALEC N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LCTX Health Care
- ALEC Health Care
- Exchange
- LCTX Nasdaq
- ALEC Nasdaq
- Market Cap
- LCTX 107.3M
- ALEC 124.0M
- IPO Year
- LCTX N/A
- ALEC 2019
- Fundamental
- Price
- LCTX $1.03
- ALEC $1.60
- Analyst Decision
- LCTX Strong Buy
- ALEC Buy
- Analyst Count
- LCTX 5
- ALEC 8
- Target Price
- LCTX $4.20
- ALEC $4.50
- AVG Volume (30 Days)
- LCTX 1.6M
- ALEC 415.3K
- Earning Date
- LCTX 08-07-2025
- ALEC 08-11-2025
- Dividend Yield
- LCTX N/A
- ALEC N/A
- EPS Growth
- LCTX N/A
- ALEC N/A
- EPS
- LCTX N/A
- ALEC N/A
- Revenue
- LCTX $9,557,000.00
- ALEC $88,339,000.00
- Revenue This Year
- LCTX N/A
- ALEC N/A
- Revenue Next Year
- LCTX $232.66
- ALEC $319.82
- P/E Ratio
- LCTX N/A
- ALEC N/A
- Revenue Growth
- LCTX 19.42
- ALEC N/A
- 52 Week Low
- LCTX $0.37
- ALEC $0.87
- 52 Week High
- LCTX $1.21
- ALEC $6.52
- Technical
- Relative Strength Index (RSI)
- LCTX 53.25
- ALEC 49.80
- Support Level
- LCTX $0.93
- ALEC $1.74
- Resistance Level
- LCTX $1.02
- ALEC $2.00
- Average True Range (ATR)
- LCTX 0.08
- ALEC 0.12
- MACD
- LCTX -0.01
- ALEC -0.01
- Stochastic Oscillator
- LCTX 35.71
- ALEC 14.93
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.